繁体中文
设为首页
加入收藏
当前位置:药品说明书与价格首页 >> 神经内科 >> 新药动态 >> Rizaport(rizatriptan/RHB-103)口服薄膜制剂-治疗急性偏头痛

Rizaport(rizatriptan/RHB-103)口服薄膜制剂-治疗急性偏头痛

2016-08-11 09:42:59  作者:新特药房  来源:互联网  浏览次数:11  文字大小:【】【】【
简介:RIZAPORT(以前RHB-103)是一种口服快速溶解薄利扎曲坦的偏头痛的治疗制剂RIZAPORT™ (Migraine/rizatriptan/RHB-103) RIZAPORT™ (formerly RHB-103) is a proprietary oral fast dissolving thin ...

RIZAPORT(利扎曲坦口服薄膜剂:以前RHB-103)是一种快速治疗偏头痛的治疗制剂


2015年11月9日,RHB-103(利扎曲普坦口服膜剂)在德国全球首次获得批准,由RedHill和IntelGenx共同开发,商品名RIZAPORT,用于治疗急性偏头痛
RIZAPORT™ (Migraine/rizatriptan/RHB-103)
RIZAPORT™ (formerly RHB-103) is a proprietary oral fast dissolving thin film formulation of rizatriptan for the treatment of migraine.
RIZAPORT™ is being co-developed with Montreal-based IntelGenx Corp. following an August 2010 RedHill-IntelGenx co-development agreement. RIZAPORT™ is planned to be indicated for the treatment of acute migraines.
In November 2015 RedHill and IntelGenx announced that Germany's BfArM granted marketing authorization of RIZAPORT™ (RHB-103) 5mg and 10mg. The national approval of RIZAPORT™ in Germany was granted under the European Decentralized Procedure (DCP), in which Germany served as the Reference Member State. This authorization is the first national marketing approval of RIZAPORT™. Marketing authorization in Luxemburg, the Concerned Member State, is expected to follow.
In March 2013, RedHill and IntelGenx submitted a New Drug Application (NDA) to the FDA seeking marketing approval of RIZAPORT™, following a positive Pre-NDA meeting with the FDA and a successful bioequivalence study. The pivotal bioequivalence clinical trial demonstrated the bioequivalence between RedHill’s oral thin-film RIZAPORT™ and Merck & Co.’s Maxalt-MLT®.
In February 2014 RedHill and IntelGenx announced that they received a Complete Response Letter (CRL) from the FDA regarding the RIZAPORT™ NDA. The FDA letter raised no questions or deficiencies relating to RIZAPORT™’s safety and bio-equivalence data, and did not require additional clinical trials. The questions raised by the FDA primarily relate to third party CMC and to the packaging and labeling of the product. RedHill and IntelGenx submitted a response to the FDA in March 2014 – FDA’s review of the RIZAPORT™ NDA continues.

责任编辑:admin


相关文章
利扎曲坦快速溶解晶片|Maxalt MLT(Rizatriptan Rapid Dissolving Wafers)
 

最新文章

更多

· Rizaport(rizatriptan/R...
· 癫痫新药Brivaraceta已获...
· FDA批准吡仑帕奈(peram...
· 帕金森新药Xadago(safin...
· FDA批准Zinbryta为治疗多...
· 多发性硬化症每月一次注...
· 欧盟批准TachoSil(人凝...
· 新一代癫痫药物Fycompa口...
· 欧盟批准Brivaracetam为...
· 美国FDA批准Briviact治疗...

推荐文章

更多

· Rizaport(rizatriptan/R...
· 癫痫新药Brivaraceta已获...
· FDA批准吡仑帕奈(peram...
· 帕金森新药Xadago(safin...
· FDA批准Zinbryta为治疗多...
· 多发性硬化症每月一次注...
· 欧盟批准TachoSil(人凝...
· 新一代癫痫药物Fycompa口...
· 欧盟批准Brivaracetam为...
· 美国FDA批准Briviact治疗...

热点文章

更多

· Rizaport(rizatriptan/R...